GO
Loading...

Medicine

More

  • Lipitor

    Pfizer has been using Dr. Robert Jarvik, the inventor of the Jarvik Artificial Heart, for quite some time now as its Lipitor "celebrity" pitchman. But recently I've noticed something remarkable creeping into his copy--the script he reads for TV and radio spots and the text that appears in the print ads.

  • Merck, Sanofi, Glaxo Get "Shot In The Arm" From U.K. Friday, 26 Oct 2007 | 12:52 PM ET

    British health authorities today announced that starting next fall, all 12- and 13-year-old girls will have to get the controversial shots to prevent the sexually transmitted virus that can lead to cervical cancer. Merck and Sanofi-Aventis are partners on the vaccine Gardasil and the UK-based GlaxoSmithKline makes a similar one Cervarix.

  • Eli Lilly: "Bloom" Is Off The Pipeline Thursday, 25 Oct 2007 | 11:43 AM ET
    Eli Lilly

    If the stock closes down at least 4.46% today (as I write this it is off nearly 7%) Eli Lilly will suffer its worst one-day loss in more than four years, according to our resident statistical expert Robert Hum. If it were to close off more than 7.79%, Hum says it would be the stock's biggest one-day fall since Oct. 23, 2002--almost five years to the day.

  • Glaxo's Avandia Nose Dive: What It Means Wednesday, 24 Oct 2007 | 11:48 AM ET

    Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.

  • Dendreon's Provenge Trial: Big Step On Bumpy Road Tuesday, 23 Oct 2007 | 2:58 PM ET

    It isn't moving the stock, but Dendreon this morning announced that it has signed up all of the patients for the big clinical trial that could lead to its prostate cancer drug, Provenge, winning Food and Drug Administration approval. The completion of enrollment was not unexpected, so that's why people aren't trading on the news.

  • Genentech And Readers Not Seeing Eye To Eye Friday, 19 Oct 2007 | 8:04 AM ET

    My recent posts on Genentech trying to crack down on doctors using its cheaper cancer drug Avastin instead of the more expensive Lucentis to treat patients with age-related macular degeneration--elicited a lot of emails from readers all over the world.

  • Pfizer "Chokes" on Inhaled Diabetic Insulin Thursday, 18 Oct 2007 | 11:29 AM ET
    Exubera

    Just months after launching what was hailed as a revolutionary new product, Pfizer is taking it off the market. And it has nothing to do with safety. It has everything to do with sales--or the lack, thereof. The world's biggest drug company only recently started direct-to-consumer advertising for Exubera, but it apparently didn't work.

  • Gilead: Has Bird Flu Fighter Tamiflu "Sickened" Stock? Wednesday, 17 Oct 2007 | 12:37 PM ET

    There was a time within the past couple of years that it seemed you couldn't open a major newspaper or watch a TV news program without seeing a story about the bird flu and Tamiflu--the antiviral medicine from Roche and Gilead Sciences. GILD invented the drug and later sold rights to Roche which pays GILD a royalty on sales.

  • JNJ, Genentech: What's Ailing Them (And Their Stock) Tuesday, 16 Oct 2007 | 11:44 AM ET

    If you saw the headline, you would've thought that Johnson and Johnson might help power the Dow today. The hybrid pharmaceutical, medical device and consumer healthcare products company handily beat the Street and raised its guidance for the year.

  • Genentech: What's Really Behind The Earnings Monday, 15 Oct 2007 | 5:02 PM ET

    Late last week, I blogged about keeping an eye on the Lucentis sales number when Genentech reports earnings. Well, the company is just out with its release and, sure enough, revenue from the drug for age-related macular degeneration (AMD) fell sequentially from the second quarter to the third quarter.

  • Alzheimer's Blood Test: Would You Take It? Monday, 15 Oct 2007 | 1:52 PM ET
    Cat scan image of human brain

    This morning on "Squawk Box" and "Squawk on the Street" I reported on a new study showing that a simple blood test might predict whether you will develop Alzheimer's Disease. The report, which appears in the scientific, peer-reviewed journal "Nature Medicine...

  • Biogen Idec: First Of A Biotech Buying Binge? Monday, 15 Oct 2007 | 12:52 PM ET

    For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.

  • Pfizer's Response On CEO Kindler's Contributions Friday, 12 Oct 2007 | 4:36 PM ET

    I blogged earlier today that I'd reached out to Pfizer for comment regarding Jeff Kindler's contribution to Sen. Hillary Clinton and would let you know if or when I heard back. Well, this just arrived in my inbox from Jack Cox with Corporate Affairs:

  • Peter Rost, who burst onto the business news landscape a few years ago as a Pfizer whistleblower and the subject of a piece on CBS' "60 Minutes", is enjoying a new career as a blogger and a reporter for Brandweek. And late yesterday he's blitzing some of his reporter contacts with this item about the apparent 180-degree change presidential politics at the world's biggest pharmaceutical company.

  • Genentech: Is Bottom Line Pushing Use of Lucentis? Friday, 12 Oct 2007 | 4:11 PM ET

    It didn't take long. Yesterday, I blogged that I'd be curious to hear what the response of doctors might be to Genentech's new crackdown on the use of Avastin instead of Lucentis for age-related macular degeneration. Today, the American Academy of Opthamology put out a press release saying the new policy "could have a significant impact on the care of patients with (AMD)."

  • Genentech: Did I Bury The Lead About Avastin? Friday, 12 Oct 2007 | 11:27 AM ET

    Yesterday I reported that Genentech had quietly buried on its web site www.gene.com the announcement of its new crackdown against using Avastin instead of Lucentis for adult-onset blindness. From the homepage, I had counted four somewhat counterintuitive clicks to get the link to the letter detailing the new policy.

  • Shortly after writing my last blog entry on Genentech's new ranking and part of the reason for its fall being blamed on the Lucentis/Avastin eye drug controversy, I came across this news item on The Wall Street Journal's Health Blog.

  • Genentech Drops In (Industry) Poll, New Number One! Thursday, 11 Oct 2007 | 2:22 PM ET

    What a week for upsets. First, the 35-game home field winning streak of my USC Trojans comes to an end at the hands of the 40-point underdog Stanford Cardinal. Then, today, Genentech's six-year reign at the top of a big industry survey is over. Boehringer Ingelheim is the new number one!

  • Medtronic: The Cents of Making Stents Thursday, 11 Oct 2007 | 10:42 AM ET

    Late yesterday an FDA panel of outside experts unanimously recommended the agency approve Medtronic's drug-coated stent called, "Endeavor". Unlike drugs, there is no telegraphed date for an agency decision, but analysts think the FDA will approve the device by the end of the year or early next year.

  • Glaxo Buys into Synta, Investors Sell Wednesday, 10 Oct 2007 | 1:08 PM ET

    Melanoma -- a type of skin cancer -- is the most common form of cancer. It can spread very quickly and the prognosis often is not good. The American Cancer Society estimates that nearly 60,000 new cases of melanoma will be diagnosed this year and more than 8,000 patients will die. You can find out more about it on the ACS's website.